Stable nimodipine tablets with high bioavailability containing NM-SD prepared by hot-melt extrusion

Powder Technology

Volumn 204, Issue 2-3, 2010, Pages 214-221

  Jijun, Fu ^a   Lili, Zhang ^a   Tingting, Guan ^a   Xing, Tang ^a   Haibing, He ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Bioavailability; Direct compression; Hot melt extrusion; Nimodipine; Solid dispersions; Stability

Indexed keywords

BIOAVAILABILITY; DIRECT COMPRESSION; HOT MELT; NIMODIPINE; SOLID DISPERSIONS;

BIOCHEMISTRY; CARBOXYLIC ACIDS; DIES; DISPERSIONS; DISSOLUTION; EXTRUSION; MELT SPINNING; RHODIUM COMPOUNDS; SILICON SOLAR CELLS;

PYRIDINE;

EUDRAGIT; NIMODIPINE; POVIDONE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISPERSION; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; HEAT TOLERANCE; HOT MELT EXTRUSION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PH; SINGLE DRUG DOSE; SOLID DISPERSION; STORAGE TEMPERATURE; TABLET COMPRESSION; TABLET FORMULATION;

EID: 77957017430     PISSN: 00325910     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.powtec.2010.08.003     Document Type: Article

References (14)

1. Chokshi R.J., Sandhu H., Iyer R.M., Shah N.H., Malick A.W., Zia H. Characterization of physical-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion process as a means to manufacture solid dispersion/solution. J. Pharm. Sci. 2005, 11:2463-2474.
2. Liu H.J., W P., Zh X.Y., Sh F., Gogos C.G. Effects of extrusion process parameters on the dissolution behavior of indomethacin in Eudragit® EPO solid dispersions. Int. J. Pharm. 2010, 383:161-169.
3. Qi S., Gryczke A., Belton P., Craig D.Q.M. Characterization of solid dispersions paracetamol and EUDRAGIT E prepared by hot-melt extrusion using thermal, microthermal and spectroscopic analysis. Int. J. Pharm. 2008, 354:158-167.
4. China Pharmacopeia, Beijing, 2005, pp. 166-167.
5. Forster A., Hempenstall J., Tucker I., Rades T. Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int. J. Pharm. 2001, 226:147-161.
6. Greenhalgh D.J., Williams A.C., Timmins P., York P. Solubility parameters as predictors of miscibility in solid dispersions. J. Pharm. Sci. 1999, 88:1182-1190.
7. Hancock B.C., Shamblin S.L., Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperature. Pharm. Res. 1995, 12:799-806.
8. Yoshioka M., Hancock B.C., Zografi G. Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J. Pharm. Sci. 1995, 84:983-986.
9. Weuts I., Kempen D., Decorte A., Verreck G., Peeters J., Brewster M., Van den Mooter G. Phase behaviour analysis of solid dispersions of loperamide and two structurally related compounds with the polymers PVP-K30 and PVP-VA64. Eur. J. Pharm. Sci. 2004, 22:375-385.
10. Zheng X., Yang R., Tang X., Zheng L.Y. Characterization of solid dispersions of nimodipine prepared by hot-melt extrusion. Drug Dev. Ind. Pharm. 2007, 33:791-802.
11. Weuts I., Kempen D., Decorte A., Verreck G., Peeters J., Brewster M., Van den Mooter G. Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64. Eur. J. Pharm. Sci. 2005, 25:313-320.
12. Matsumoto T., Zografi G. Physical properties of solid molecular dispersions of Indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to Indomethacin crystallization. Pharm. Res. 1999, 16:1722-1728.
13. Van den Mooter G., Wuyts M., Blaton N., Busson R., Grobet P., Augustijns P., Kinget R. Physical stabilization of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur. J. Pharm. Sci. 2001, 12:261-269.
14. Zheng X., Yang R., Zhang Y., Wang Z.J, Tang X., Zheng L.Y. Bioavailability in beagle dogs of nimodipine solid dispersions prepared by hot-melt extrusion. Drug Dev. Ind. Pharm. 2007, 33:783-789.